Inhaler monitoring company Adherium has named Peter Stratford as CEO and Mike Motion as Chief Commercial Officer, replacing interim CEO Jeremy Curnock Cook and interim CCO Bill Hunter. Stratford was most recently Head of Innovation at healthcare company BTG, which has now been acquired by Boston Scientific. Motion was most recently Head of Varithena, a BTG drug/device product for varicose veins, and was formerly Head of Digital Innovation at BTG.
Adherium has gone through a number of management changes over the past few years, with founder Garth Sutherland stepping down as CEO in 2017 and Arik Anderson taking over that role. In December 2018, the company announced that it would reorganize, with Anderson and other executives leaving and “a significant contraction in workforce.”
In August 2019, Adherium announced a partnership with Summatix for access to data from Adherium’s Hailie inhaler monitoring sensors on the Summatix medical data platform. In November 2019, the company said that it had received $1.1 million in secured debt note financing from Trudell Medical Limited.
Curnock Cook commented, “The appointments of Peter and Mike are a key step and an important phase of Adherium’s global business growth and commercialization. This transition of control at the top of the company is a very considered step by the board. This is new and top caliber experience to lead the company into its commercial growth phase to strive to deliver the promise of this technology. We welcome them to our team. Their experience with product commercialization combined with our award-winning Hailie products and technology platform will position Adherium to grow as a market leader in digital health.”
Stratford said, “Adherium has some of the best technology in this space and our goal is to bring this to a successful commercial position. I look forward to leading the organization to bring the benefits of the Hailie solution to patients.”
Read the Adherium press release.
